Cancer Genetics Signs Biomarker Services Deal with H3 Biomedicine | GenomeWeb

NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has signed a deal to provide clinical biomarker services to Eisai subsidiary H3 Biomedicine to support its development of H3B-8800, a small molecule drug candidate for certain blood cancers.

Cancer Genetics said it will specifically use next-generation sequencing, RNA expression profiling, and other technologies to provide biomarker-driven insights related to target engagement and patient response in a multi-center Phase I clinical trial of H3B-8800.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Sponsored by

This webinar will discuss a project that sought to understand the parent-of-origin epigenetic mechanisms that regulate seed development in plants, with a particular emphasis on differentiating the maternal or paternal origin of epigenetics marks.

Sponsored by

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.